STRIVE clinical trial successfully met all primary endpoints demonstrating the efficacy and safety of rezafungin for the treatment of invasive fungal infections Rezafungin data featured in one oral and three poster presentations showcase broad clinical utility of Cidara's novel once-weekly antifungal agent SAN DIEGO - Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced the presentation of data from the company's Phase 2 STRIVE trial of rezafungin at IDWeek…

SAN DIEGO - Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that the first trial site has been activated for ReSTORE, a Phase 3 clinical trial evaluating the efficacy and safety of the company's lead antifungal, rezafungin, to treat candidemia and invasive candidiasis. Rezafungin is a novel echinocandin antifungal being developed as a once-weekly, high-exposure therapy for the treatment and prevention of serious invasive fungal infections. "Given the…

Rezafungin designated for the prevention of invasive fungal infections in adults undergoing bone marrow transplantation SAN DIEGO - Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that the U.S. Food and Drug Administration (FDA) has granted both Qualified Infectious Disease Product (QIDP) and Fast Track designations for the company's prophylaxis (prevention) development program for lead antifungal product candidate, rezafungin for injection. Specifically, the QIDP designation is for the…

SAN DIEGO, Sept. 24, 2018 -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that Jeffrey Stein, Ph.D., president and chief executive officer of Cidara, is scheduled to present at two upcoming investor conferences. 2018 Cantor Global Healthcare Conference, New York, October 1, 2018 at 9:30 a.m. EDT (6:30 a.m. PDT) Ladenburg Thalmann 2018 Healthcare Conference, New York, October 2, 2018 at 8:30 a.m. EDT (5:30 a.m. PDT)…

Former Head of Global Government Affairs and Policy at Gilead Sciences led wide-ranging collaborations with leading academic institutions and non-profit groups SAN DIEGO - Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced the appointment of industry leader David Gollaher, Ph.D., to the company's Board of Directors. "With more than 30 years of experience in the biopharma and healthcare industry, Dr. Gollaher is an outstanding addition to our Board,"…

Presentations will highlight data demonstrating the broad clinical utility, safety and potency of rezafungin to fight invasive fungal infections SAN DIEGO - Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that data demonstrating the broad clinical utility and potency of the company's lead antifungal product candidate, rezafungin, will be presented at IDWeek 2018, being held October 3-7 in San Francisco. Four separate IDWeek presentations will focus on rezafungin,…

Data highlight potential of Cloudbreak immunotherapy candidates for the treatment of multi-drug resistant Gram-negative bacterial infections SAN DIEGO - Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that new data highlighting the company's innovative Cloudbreak™ immunotherapy discovery platform will be presented at two upcoming conferences. Cloudbreak is a novel platform that pairs potent antimicrobials with agents that redirect the immune system to destroy fungal, bacterial and viral pathogens.…

SAN DIEGO, Aug. 08, 2018 -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today reported financial results for the three months ended June 30, 2018 and provided an update on its corporate activities and product pipeline. "The financing commitments we secured in the second quarter provide significant funding for the company, including support for the Phase 3 clinical trials of rezafungin for the treatment of candidemia and invasive candidiasis…

Data Will Highlight Potential Advantages of Rezafungin for the Treatment and Prevention of Invasive Fungal Infections SAN DIEGO - Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that Dr. Taylor Sandison, chief medical officer, will present clinical efficacy and safety data for the company's lead antifungal rezafungin for the treatment and prevention of invasive fungal infections at two upcoming, global infectious disease conferences. Abstracts highlighting rezafungin data have…

Four accepted presentations include a late-breaker featuring Phase 2 STRIVE trial data and three posters describing the activity of rezafungin against fungal pathogens SAN DIEGO - Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, today announced that it will present four posters highlighting data from preclinical studies and a clinical trial of rezafungin, its lead antifungal product candidate, at the American Society for Microbiology (ASM) Microbe 2018, being held June 7-11…